Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Reports Results for the Fourth Quarter and Full Year 2020

Mar 23, 2021 4:01pm EDT

Aptose Expands Senior Leadership Team

Mar 16, 2021 7:30am EDT

Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021

Mar 02, 2021 4:02pm EST

Aptose Presents Highlights from ASH and Corporate Update Event

Dec 06, 2020 5:30pm EST

Aptose to Hold Corporate Update Sunday, December 6th

Dec 01, 2020 7:30am EST

Aptose Reports Results for the Third Quarter 2020

Nov 10, 2020 4:01pm EST

Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting

Nov 04, 2020 10:17am EST

Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020

Oct 27, 2020 4:01pm EDT

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

Oct 19, 2020 7:00am EDT

Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Sep 15, 2020 7:30am EDT
RSS
  • Prev
    • 1...
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences